Anti-Mouse EpCAM (CD326) - Biotin

Contact us
Leinco Technologies
Product Code: LEI-C730
Product Group: Primary Antibodies
CodeSizePrice
LEI-C730-50ug50 ug£154.00
Quantity:
LEI-C730-100ug100 ug£191.00
Quantity:
LEI-C730-500ug500 ug£287.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rat
Antibody Isotype: Rat IgG2a κ
Antibody Clonality: Monoclonal
Antibody Clone: G8.8
Regulatory Status: RUO
Target Species: Mouse
Applications:
  • Flow Cytometry
  • Immunohistochemistry (IHC)
Shipping:
2 - 8°C Wet Ice
Storage:
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Further Information

Antigen Distribution:
EpCAM is expressed in many epithelial tissues from very early embryos to adult animals and is a cell surface marker on various stem and progenitor cells. EpCAM is also an important carcinoma marker highly expressed on a variety of carcinomas, including epithelial tumors and acute myeloid leukemia. EpCAM is enriched in the basolateral membrane of mouse and human intestinal epithelium and is localized to tight junctions, adherens junctions, and the lateral membranes of epithelial cells lining the intestines.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Biotin
Format:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
TE-71 thymic epithelial cell line
Long Description:
Epithelial cell adhesion molecule (EpCAM; also known as CD326 or Tacstd1) is a 40 kDa type I transmembrane glycoprotein composed of an extracellular domain, single transmembrane domain, and the intracellular domain Ep1CD1. EpCAM functions in cell adhesion, signaling, differentiation, migration, proliferation, formation and maintenance of organ morphology, and morphogenic movements during gastrulation. Additionally, EpCAM is essential for cell junctions; the AxxxG motif in the transmembrane domain of EpCAM associates directly with claudin-7, an important tight junction protein. EpCAM also suppresses or enhances E-cadherin function depending on the context of the interaction. Mutant animal models have been developed in mouse (at least four global EpCAM knockout types and one conditional knockout), zebrafish, and Xenopus. Dysregulation and/or mutations are associated with congenital tufting enteropathy (CTE), which causes lethal diarrhea in newborns, cholestatic liver diseases, and cancer1. EpCAM promotes the proliferation of tumors, is involved in tumorigenesis and metastasis, and EpCAM positive cells serve as cancer stem cells for various human cancers. Therapeutic approaches targeting EpCAM are under development to eliminate chemotherapeutic drug resistance in cancer stem cells by conjugating cancer stem cells targeting EpCAM aptamer with a chemotherapeutic drug. Additionally, EpCAM antibody sensitizes chemoresistant myeloid leukemia to innate immune cells, and EpCAM peptide-primed dendritic cell vaccinations exhibit anti-tumor immunity in hepatocellular carcinoma cells. Monoclonal antibody G8.8 was raised against glycoconjugates isolated from the TE-71 mouse thymic epithelial cell line2. Splenic cell suspensions were fused with X63-Ag8.653 cells and the resulting hybridomas were screened on frozen Balb/c thymus.
NCBI Gene:
17075
Target:
CD326

References

1. Huang L, Yang Y, Yang F, et al. Int J Mol Med. 42(4):1771-1785. 2018. 2. Farr A, Nelson A, Truex J, et al. J Histochem Cytochem. 39(5):645-653. 1991. 3. Li H, Hsu HC, Wu Q, et al. Nat Commun. 5:4259. 2014. 4. Wang J, Wang D, Chu K, et al. Nat Commun. 10(1):4966. 2019. 5. Mart?nez LE, Garcia G Jr, Contreras D, et al. J Virol. 94(9):e00067-20. 2020. 6. Petersen B, Wolf M, Austermann J, et al. EMBO J. 32(1):100-111. 2013. 7. Snitow M, Lu M, Cheng L, et al. Development. 143(20):3733-3741. 2016. 8. Kazakevych J, Denizot J, Liebert A, et al. Genome Biol. 21(1):64. 2020. 9. Maaser K, Borlak J. Br J Cancer. 99(10):1635-1643. 2008. 10. Kuan II, Liang KH, Wang YP, et al. Sci Rep. 7:41852. 2017. 11. Kuroki S, Maeda R, Yano M, et al. Stem Cell Reports. 15(2):424-438. 2020. 12. Papadopoulou AS, Dooley J, Linterman MA, et al. Nat Immunol. 13(2):181-187. 2011. 13. Goldman O, Han S, Sourisseau M, et al. Cell Stem Cell. 12(6):748-760. 2013. 14. Shim EJ, Bang BR, Kang SG, et al. J Immunol. 191(5):2764-2770. 2013. 15. de Jong JH, Rodermond HM, Zimberlin CD, et al. Sci Rep. 2:271. 2012. 16. Liu Z, Guo W, Zhang D, et al. Sci Rep. 6:39808. 2016. 17. Freire T, Zhang X, D?riaud E, et al. Blood. 116(18):3526-3536. 2010. 18. Naus S, Blanchet MR, Gossens K, et al. Am J Respir Crit Care Med. 181(12):1318-1328.2010. 19. Cook BD, Liu S, Evans T. Blood. 16;117(24):6489-6497. 2011. 20. Krishnamurthy B, Chee J, Jhala G et al. Diabetes. 61(2):425-435. 2012. 21. El-Zaatari M, Kao JY, Tessier A, et al. PLoS One. 8(3):e58935. 2013. 22. Magness ST, Puthoff BJ, Crissey MA, et al. Am J Physiol Gastrointest Liver Physiol.305(8):G542-551. 2013. 23. Tata PR, Mou H, Pardo-Saganta A, et al. Nature. 503(7475):218-223. 2013. 24. Fischedick G, Wu G, Adachi K, et al. Stem Cell Res. 13(2):300-315. 2014. 25. Velardi E, Tsai JJ, Holland AM, et al. J Exp Med. 211(12):2341-2349. 2014. 26. Clatworthy MR, Aronin CE, Mathews RJ, et al. Nat Med. 20(12):1458-1463. 2014. 27. Thelemann C, Eren RO, Coutaz M, et al. PLoS One. 9(1):e86844. 2014. 28. Walmsley GG, Rinkevich Y, Hu MS, et al. Tissue Eng Part C Methods. 21(3):314-321. 2015. 29. Xia H, Ren X, Bolte CS, et al. Am J Respir Cell Mol Biol. 52(5):611-621. 2015. 30. Goto Y, Lamichhane A, Kamioka M, et al. Sci Rep. 5:15918. 2015. 31. Satoh R, Kakugawa K, Yasuda T, et al. PLoS Genet. 12(1):e1005776. 2016. 32. Shi Y, Wu W, Chai Q, et al. Nat Commun. 7:12369. 2016. 33. Cuccarese MF, Dubach JM, Pfirschke C, et al. Nat Commun. 8:14293. 2017. 34. Yamaji M, Jishage M, Meyer C, et al. Nature. 543(7646):568-572. 2017. 35. Lim JS, Ibaseta A, Fischer MM, et al. Nature. 545(7654):360-364. 2017. 36. Lopes N, Vachon H, Marie J, et al. EMBO Mol Med. 9(6):835-851. 2017. 37. Nikolaidis NM, Noel JG, Pitstick LB, et al. Proc Natl Acad Sci U S A. 114(32):E6613-E6622.2017 38. Koh AS, Miller EL, Buenrostro JD, et al. Nat Immunol. 19(2):162-172. 2018. 39. Lopes N, Charaix J, C?dile O, et al. Nat Commun. 9(1):1262. 2018. 40. Moretti FA, Klapproth S, Ruppert R, et al. Elife. 7:e35816. 2018. 41. Thilakasiri P, Huynh J, Poh AR, et al. EMBO Mol Med. 11(4):e9539. 2019. 42. Glal D, Sudhakar JN, Lu HH, et al. Front Immunol. 9:2522. 2018. 43. Wang X, Yang L, Wang YC, et al. Cell Res. 30(12):1109-1126. 2020. 44. Giraud J, Foroutan M, Boubaker-Vitre J, et al. Transl Oncol. 14(2):101001. 2021. 45. Goga A, Yagabasan B, Herrmanns K, et al. Nat Commun. 12(1):3339. 2021. 46. Mauduit O, Aure MH, Delcroix V, et al. Cell Rep. 39(2):110663. 2022. 47. Ferreirinha P, Pinheiro RGR, Landry JJM, et al. Development. 149(10):dev200513. 2022.